Hepatitis B Vaccination Practices in Hospital Newborn Nurseries Before and After Changes in Vaccination Recommendations.
Clark, Sarah J. MPH; Cabana, Michael D. MD, MPH; Malik, Tasneem MPH; Yusuf, Hussain MBBS, MPH; Freed, Gary L. MD, MPH
[Article]
Archives of Pediatrics & Adolescent Medicine.
155(8):915-920, August 2001.
(Format: HTML)
Background: Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available.
Objective: To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably).
Design: A telephone survey of a random sample of 1000 US hospitals.
Participants: Nurse managers, nursery directors, and staff nurses of the newborn nurseries.
Main Outcome Measures: Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine.
Results: Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7, 1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants.
Conclusions: Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.
Arch Pediatr Adolesc Med.2001;155:915-920
Copyright 2001 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.